525 results on '"Carlino, Matteo S."'
Search Results
2. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
3. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response
4. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
5. PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
6. Melanoma medicine: New drugs for melanoma and the role of the general practitioner
7. A gut microbial signature for combination immune checkpoint blockade across cancer types
8. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
9. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma
10. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
11. Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
12. Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy
13. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
14. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
15. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
16. Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma
17. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
18. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
19. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
20. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
21. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
22. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
23. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
24. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
25. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
26. Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
27. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
28. Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
29. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
30. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
31. IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics
32. Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?
33. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
34. Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets
35. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
36. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes
37. Clinical and genomic correlates of imatinib response in melanomas with KIT alterations
38. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
39. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
40. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
41. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
42. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
43. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
44. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
45. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
46. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
47. Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location
48. Immune checkpoint inhibitors in melanoma
49. High response rate to PD-1 blockade in desmoplastic melanomas.
50. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.